Promoted Content
Promoted Content

Find Novel Drugs for Rare Diseases and Disorders under Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Enzyme replacement therapy

            Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Chiesi Group

            Deal Size: $150.0 million Upfront Cash: $1.2 million

            Deal Type: Licensing Agreement November 03, 2020

            Details:

            XOMA gains rights to future milestone and royalty revenues associated with the advancement of the enzymes being investigated as potential treatments for four different lysosomal storage disorders (LSD) under Bioasis’ strategic alliance with Chiesi Group.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OMNI nuclease

            Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Anges

            Deal Size: $61.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing January 15, 2020

            Details:

            The funding will accelerate novel OMNI gene editing platform into a broad therapeutic product pipeline.